bioRxivCancer BiologyPreprint
Rapid expansion of podoplanin-positive fibroblasts following radiation limits the anti-tumour CD8+ T-cell response to radiotherapy.
Anna Clare WilkinsiD, Spyridon MakrisiD, Mary J. GreeniD, Steven HooperiD, Anna MikolajczakiD, Giovanni GiangrecoiD, Srinivas AllankiiD, Emma L. NyeiD, Emma Connick, Richard MitteriD, Sam Cooper, Emily DurieiD, Malin PederseniD, Amy BurleyiD, Katie O’FeeiD, Ben O’LearyiD, Daniel ShewringiD, Zoe Ramsden, Alan A. MelcheriD, Kevin Joseph HarringtoniD, Navita SomaiahiD, Sophie E. ActoniD, Erik A. SahaiiD
Abstract
Radiotherapy is known to cause changes in the tumour stroma which can undermine treatment efficacy. Our understanding of this process has historically centred around effects driven by Transforming Growth Factor-beta (TGF-{beta}) and alpha-smooth muscle actin (-SMA)+ fibroblasts. Here, we identified a rapid expansion of podoplanin (PDPN)+ fibroblasts following radiotherapy in breast, head and neck and melanoma tumours. This fibrosis was not dependent on TGF-{beta}, but was downstream of a radiotherapy-induced adaptive immune response. CD8+ T-cells entering the tumour after radiation were sequestered at the interface between residual tumour cells and PDPN+ fibroblasts and failed to enter the tumour core. Genetic deletion of PDPN in fibroblasts impacted their cytoskeleton and ability to organise extracellular matrix. This was associated with increased CD8+ T-cell entry and spontaneous tumour regression. Overall, we identify a mechanism whereby PDPN+ fibrosis limits immune-mediated radiation cell kill and demonstrate that disruption of PDPN signalling favours tumour control. SignificanceIn this study we show that rapid podoplanin (PDPN)+ fibroblast expansion following radiotherapy limits immune-mediated radiation cell kill. Targeting PDPN and associated downstream signalling improves tumour control and is a promising strategy in combination with radiotherapy. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=175 SRC="FIGDIR/small/680949v1_ufig1.gif" ALT="Figure 1"> View larger version (61K): org.highwire.dtl.DTLVardef@1711bb0org.highwire.dtl.DTLVardef@d0c3a1org.highwire.dtl.DTLVardef@1db88adorg.highwire.dtl.DTLVardef@1ea3ab6_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: cell-cell communication
- research focus: cell type annotation
- approach: experimental assay
- approach: wet-lab / biochemical assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pre-existing intratumoral stem-like CD8+ T-cells drive radiotherapy-induced tumor control
Hakan Köksal, Michael Herbst, … Maries F. van den Broek·Cell ReportsPeer-reviewed·Apr 1, 2025
- Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity
P. Kroon, E. Frijlink, … I. Verbrugge·bioRxiv·Jun 29, 2018
- Timing anti-PD-L1 checkpoint blockade immunotherapy to enhance tumor irradiation
Seung Young Lee, Joanna Pagacz, … Stephen J. Kron·CancersPeer-reviewed·Jan 24, 2025
- Targeting STING-ATM axis overcomes radiotherapy-induced immune suppression and restores anti-tumor immunity in nasopharyngeal carcinoma
Tzu-Tung Liu, Kai-Ping Chang, … Shu‐Chen Liu·bioRxiv·Nov 12, 2025
- IL15/IL15Rα complex induces an anti-tumor immune response following radiation therapy only in the absence of Tregs and fails to induce expansion of progenitor TCF1+ CD8 T cells
Miles Piper, Chloe A. Hodgson, … Sana D. Karam·Molecular Cancer TherapeuticsPeer-reviewed·Sep 2, 2025
- Proton FLASH radiotherapy enhances control of triple-negative breast cancer through STING-IRF3 and CD8+ T-cell immunity
Pierre Loap, Ioannis Paraskevaidis, … Ioannis I. Verginadis·bioRxiv·Sep 22, 2026